• NPPA orders monitoring of revised prices for 137 anti-cancer drugs.
• New prices effective from November 9, 2026.
• State Drug Controllers asked to ensure patient benefits and compliance.
• Action Taken Reports due by November 16.

GG News Bureau
New Delhi, 13th Nov: The National Pharmaceutical Pricing Authority (NPPA) has directed strict monitoring of revised prices of 137 anti-cancer drugs, following the implementation of Trade Margin Rationalisation (TMR) measures from November 9.

The revised prices were notified through a Gazette order dated October 17, 2026. The latest price lists, updated with company submissions received up to November 11, are available on the NPPA website and the Pharma Sahi Daam app and portal.

The NPPA has instructed manufacturers, retailers, dealers, stockists, hospitals and medical institutions to comply with the revised prices. They must also prominently display updated price lists at their premises and on their websites.

State Drug Controllers have been asked to closely monitor compliance and ensure that patients receive the benefit of the revised maximum retail prices (MRPs).

The authority has warned that violations could lead to overcharging proceedings under the provisions of the Drugs (Prices Control) Order, 2013.

Consumers can report complaints related to overcharging, shortage or non-availability of medicines through the Pharma Sahi Daam app or portal. Complaints can also be registered through the NPPA helpline at 1800-111-255 or by email at monitoring-nppa@gov.in.

State Drug Controllers have been directed to submit their Action Taken Reports to the NPPA by November 16, 2026.